Healey lashes out at biotech firm over ‘unfair’ drug prices

BOSTON – Massachusetts Attorney General Maura Healey may go after Gilead Sciences over the price of its new hepatitis C treatment, Sovaldi, calling the $84,000 cost of a full treatment against the deadly disease potentially an illegal unfair trade practice.
Healey referred to pricing for the drug as well as another hepatitis C treatment called Harvoni in speech Wednesday to members of the state's biotechnology industry, appealing to them for greater transparency in the way prices are set. She also called for making health care accessible to those who need it.